The Cdc25 dual speci®city phosphatase family has a central role in controlling cell cycle progression and has been implicated in the etiology of cancer. One compound, 4-(benzyl-(2-[(2, 5-diphenyl-oxazole-4-carbonyl)-amino]-ethyl)-carbamoyl)-2-decanoylamino butyric acid (SC-aad9), was previously identi®ed as the most potent reported synthetic inhibitor of Cdc25 phosphatases in vitro. In the present study, we demonstrate that SC-aad9 inhibited Cdc25-dependent cell cycle progression at both G1 and G2/M phase using tsFT210 cells, which express a temperature-sensitive Cdc2 mutant. SCaad9 blocked both G2/M transition and dephosphorylation of Cdc2 in a concentration-dependent manner. SCaad9 also enhanced tyrosine phosphorylation of both Cdk2 and Cdk4, and decreased Cdk4 kinase activity. Both of the kinases are potent regulators of G1 transition. Furthermore, closely related chemical analogs that lacked Cdc25 inhibitory activity failed to block cell cycle progression at both G1 and G2/M, and did not aect Cdc2 phosphorylation or Cdk4 kinase activity. SC-aad9 did not alter p53, p21 or p16 levels. Our results support the hypothesis that the disruption in cell cycle transition caused by SC-aad9 was due to intracellular Cdc25 inhibition. We propose that the SC-aad9 pharmacophore could be useful in further clarifying the role of Cdc25 phosphatase-dependent pathways in checkpoint control, oncogenesis, and apoptosis.
Introduction
Cdc25 phosphatases play a key role in cell cycle progression by activating cyclin-dependent kinases (Cdk). In mammalian cells, Cdc25 phosphatases are encoded by a multigene family consisting of Cdc25A, B and C (Galaktinov and Beach, 1991; Nagata et al., 1991; Sadhu et al., 1990) . Each Cdc25 homolog controls distinct aspects of cell cycle progression. Cdc25C dephosphorylates and activates the mitotic kinase Cdc2/cyclin B, which is required for entry into mitosis (Homann et al., 1993; Izumi and Maller, 1993; Millar et al., 1991; Strausfeld et al., 1994) . Cdc25A is important for entry into S phase (Homann et al., 1994; Jinno et al., 1994) , while Cdc25B is essential for preinitiating G2/M transition and S phase progression (Garner-Hamrick and Fisher, 1998; Lammer et al., 1998) .
Cdc25A and B have oncogenic properties in cells that have mutated Ha-ras or loss of the retinoblastoma susceptibility gene (Rb1) (Galaktionov et al., 1995b) . Cdc25A and B are also transcriptional targets of the cmyc oncogene (Galaktionov et al., 1996) . Furthermore, Cdc25A and B are overexpressed in breast (Galaktionov et al., 1995b) , head and neck (Gasparotto et al., 1997) , non-Hodgkin's lymphoma (Hernandez et al., 1998) , and non-small cell lung cancer (Wu et al., 1998) ; overexpression may re¯ect poor prognosis (Galaktionov et al., 1995b; Hernandez et al., 1998) . Thus, inhibitors of Cdc25 phosphatases are attractive as potential anti-cancer agents.
We have previously described the combinatorial synthesis of a library of small molecules designed as inhibitors of protein phosphatases . One member of the targeted array library, 4-(benzyl-(2-[(2,5-diphenyl-oxazole-4-carbonyl)-amino]-ethyl)-carbamoyl)-2-decanoylamino butyric acid (SC-aad9) ( Figure  1 ), eectively inhibited protein tyrosine phosphatase 1B (PTP1B) and Cdc25 dual speci®city phosphatases, but not protein serine/threonine phosphatase (PSTPase) at low micromolar concentrations in vitro . Interestingly, this compound selectively inhibited growth of simian virus 40 (SV40) large T antigen transformed cell lines, which is a model of a malignant phenotype that overexpresses Cdc25B . Prolonged exposure of cells to SC-aad9 also disrupted insulin-like growth factor-1 (IGF-1) signaling pathways and down-regulated Cdc2 . Nevertheless, the mechanisms responsible for the antiproliferative activity of SC-aad9 remain unclear.
In this report, we used synchronized tsFT210 cells, which are a temperature sensitive Cdc2 mutant isolated from the mouse mammary carcinoma cell line FM3A (Th'ng et al., 1990) . We demonstrate for the ®rst time that SC-aad9 caused intracellular perturbations consistent with inhibition of Cdc25; namely cellular Cdk2 and Cdk4 tyrosine phosphorylation, decreased Cdk4 kinase activity and increased the phosphorylation level of Cdc2 in these cells. We also found SC-aad9 arrested tsFT210 cells at both G1 and G2/M consistent with the essential role Cdk2, Cdk4 and Cdc2 have in controlling these cell cycle checkpoints. Closely related chemical analogs that lacked in vitro Cdc25 inhibitory activity failed to block both G1 and G2/M cell cycle progressions, and did not aect Cdc2 phosphorylation or Cdk4 kinase activity, suggesting that the antiproliferative activity of the compound was due to Cdc25 inhibition.
Results
SC-aad9 arrested synchronous tsFT210 cell cycle progression at G2/M tsFT210 cells incubated at the permissive temperature of 32.08C have a normal cell cycle distribution ( Figures  2a and 4a ), but cells arrested at G2/M when incubated at the non-permissive temperature of 39.48C, because of p34 cdc2 inactivation (Figures 2b and 4b ). When G2/M arrested cells were cultured at the permissive temperature for 6 h with dimethyl sulfoxide (DMSO) vehicle alone, we saw clear evidence of entry into G1 ( Figure  2c ). In contrast, 1 mM nocodazole did not permit cell passage through G2/M (Figure 2d ). To determine the eect of SC-aad9 on G2/M cell cycle transition, we treated cells with SC-aad9 (100 mM) for 6 h after releasing at 32.08C. As indicated in Figure 2g , SCaad9 signi®cantly arrested cells at G2/M phase. This G2/M inhibition was dependent on the SC-aad9 concentration. Cells treated with 25 mM SC-aad9 had no obvious dierences in cell cycle distribution compared with cells exposed to the DMSO vehicle (Figure 3a,b) . Concentrations of 50 mM SC-aad9 slightly inhibited, and 75 or 100 mM signi®cantly inhibited the cell cycle progression at G2/M (Figure 3a ,c ± e).
SC-aad9 arrested synchronous tsFT210 cell cycle progression at G1
We next attempted to determine whether or not SCaad9 caused G1 arrest in tsFT210 cells. Previous studies indicated SC-aad9 did not directly inhibit Cdc2 kinase activity . To investigate the mechanism of G1 cell cycle block by SC-aad9, we arrested tsFT210 cells at G2/M by shifting to the nonpermissive temperature, released them into G1 by shifting to the permissive temperature, and added SCaad9 or vehicle 6 h later. The cells that were treated with the DMSO vehicle passed through G1 phase and produced the broad S phase peak (Figure 4d ), while cells exposed continuously to 50 mM roscovitine were blocked and did not pass through G1 (Figure 4e ). The cells treated with 100 mM SC-aad9 also did not pass through G1 (Figure 4h ). As expected from our previous studies (Figure 2 ), SC-aad9 not only caused a G1 block but also prevented cells that were in the G2 phase from progressing through G2/M, which resulted in two prominent cell cycle peaks (Figure 4h ). Concentration escalation studies revealed that G1 inhibition occurred with approximately 50 mM SCaad9 in the synchronous tsFT210 cells (Figure 3f ± j) .
SC-aad9 increased the phosphorylation level of Cdc2 in synchronous tsFT210 cells
One of the putative substrates for both Cdc25B and Cdc25C is the mitotic inhibitor Cdc2, which must be Figure 1 Chemical structures of SC-aad9, SC-aa09 and FY2-aa09. FY2-aa09 comprises a 18 : 82 mixture of the upper and lower components Figure 2 Inhibition of tsFT210 cell cycle progression at G2/M by SC-aad9. TsFT210 cells were cultured at the permissive temperature of 32.08C (a), and then incubated for 17 h at the non-permissive temperature of 39.48C (b). Cells were released from cycle arrest by shifting to the 32.08C medium. The cells were then incubated for 6 h in the presence of DMSO vehicle (c), 1 mM nocodazole (d), 100 mM FY2-aa09 (e), 100 mM SC-aa09 (f), or 100 mM SC-aad9 (g). Fluorescence corresponding to 2C and 4C DNA content are represented by vertical bars. Results are representative of at least three independent experiments Figure 3 Concentration dependent G2/M and G1 arrest in tsFT210 cells by SC-aad9. The synchronized tsFT210 cells were released by incubation at 32.08C and treated immediately with DMSO vehicle alone (a) or 25 mM (b), 50 mM (c), 75 mM (d), 100 mM (e), SC-aad9, respectively, to probe for G2/M arrest. Cells were also treated 6 h after releasing with DMSO vehicle alone (f) or 25 mM (g), 50 mM (h), 75 mM (i), 100 mM (j) SC-aad9, respectively, to probe for G1 arrest. Fluorescence corresponding to 2C and 4C DNA contents are represented by vertical bars dephosphorylated to allow entry into mitosis (Lammer et al., 1998; Sebastian et al., 1993; Strausfeld et al., 1994; Th'ng et al., 1990) . Thus, we reasoned an eective Cdc25 inhibitor would cause G2/M cell cycle block and performed Western blotting on tsFT210 cell extracts to determine Cdc phosphorylation levels in the presence or absence of SC-aad9. Protein lysates of tsFT210 cells arrested at the G2/M boundary were harvested and analysed by SDS ± PAGE. Approximately 50% of Cdc2 was in the mitotic-inactive hyper-phosphorylated form as re¯ected by a slower migrating Cdc2 ( Figure 5 ). The phosphorylation of Cdc2 decreased gradually after cells were released from G2/M block, and most of the Cdc2 was dephosphorylated 6 h after G2/M release. While Cdc2 in tsFT210 cells was dephosphorylated in the presence of 25 mM SC-aad9, Cdc2 dephosphorylation was partially blocked with 50 mM SC-aad9 and completely blocked with 100 mM ( Figure 5 ). When we incubated cells with 1 mM nocodazole, which caused G2/M arrest, no hyper-phosphorylation of Cdc2 was seen consistent with its proposed inhibitory activity after p34 cdc2 activation.
To quantify the phosphorylation level of Cdc2 precisely, we determined by densitometry the intensity of both phosphorylated and unphosphorylated bands, respectively, and calculated a phosphorylation ratio as described in Materials and methods. The ratio of phosphorylated to unphosphorylated Cdc2 decreased with a t 1/2 of approximately 2 h ( Figure 6 ). SC-aad9 (25 mM) did not alter the phosphorylation ratio. Six hours after 50 and 100 mM SC-aad9, however, the phosphorylation level of Cdc2 was increased in a concentration dependent manner. We speculate that the initial decrease seen in Cdc2 phosphorylation at 2 h with both 50 and 100 mM SC-aad9 may re¯ect the time required for the compound to enter cells and inhibit Cdc25 while the subsequent increase in Cdc2 phosphorylation could be due to kinase activity during Cdc25 inhibition.
SC-aad9 tyrosine phosphorylated Cdk2 and Cdk4 in synchronous tsFT210 cell
Cdk4 plays a central role in regulating the G1 transition by its association with cyclin D1 (Hunter and Pines, 1994) . Cdk2 is also involved in regulating the G1/S transition by its association with cyclin E or cyclin A. Cdk2/cyclin E complex has been shown to be dephosphorylated at Thr14 and Tyr15 and activated by Figure 4 Inhibition of cell cycle progression at G1 by SC-aad9 in tsFT210 cells. TsFT210 cells were cultured at the permissive temperature of 32.08C (a), and then incubated for 17 h at the non-permissive temperature of 39.48C (b). Cells were re-incubated at 32.08C for 6 h (c), and then incubated for an additional 6 h in the presence of DMSO vehicle (d), 50 mM roscovitine (e), 100 mM FY2-aa09 (f), 100 mM SC-aa09 (g), 100 mM SC-aad9 (h). Fluorescence corresponding to 2C and 4C DNA content are represented by vertical bars. Results are representative of at least three independent experiments Figure 5 Inhibition of dephosphorylation of Cdc2 by SC-aad9 in synchronous tsFT210 cells. G2/M synchronous tsFT210 cells were treated with 0, 25, 50, or 100 mM SC-aad9, and re-entered the cell cycle by culturing at 32.08C. After 0, 2, 4, or 6 h incubation at the permissive temperature, the protein lysates of tsFT210 were harvested and analysed by Western blotting for Cdc2. P and U corresponds to phosphorylated and unphosphorylated Cdc2, respectively Figure 6 Cdc2 phosphorylation ratio (P/U) after exposure of SC-aad9. Phosphorylation ratio was calculated after cell exposure to 0 mM (open square), 25 mM (open circle), 50 mM (closed square), or 100 mM (closed circle) SC-aad9 for 0, 2, 4, or 6 h, respectively. The phosphorylation ratio (P/U) was calculated by using the formula: P/U=(a)/(b), where (a) was the intensity of the phosphorylated band and (b) was the intensity of the unphosphorylated band, respectively Dual G1 and G2/M inhibition by SC-aad9 K Tamura et al Cdc25A treatment in vitro (Homann et al., 1994; Sebastian et al., 1993) . To clarify the mechanism of G1 cell cycle block by SC-aad9, we treated tsFT210 cells with 4100 mM SC-aad9 for 6 h, immunoprecipitated Cdk2 or Cdk4 from the cell lysates, and then determined tyrosine phosphorylation by Western blotting, using anti-phosphotyrosine monoclonal antibody. While we con®rmed an equivalent loading of Cdk2 or Cdk4 with anti-Cdk2 or anti-Cdk4 antibody, respectively, both tyrosine phosphorylated Cdk2 and Cdk4 increased after SC-aad9 treatment (Figure 7a,b) . To estimate the phosphorylation level of Cdk2 or Cdk4 quantitatively, we determined the intensity of the bands by densitometer, and calculated a phosphorylation level as described in Materials and methods. Both tyrosine phosphorylated Cdk2 and Cdk4 signi®cantly increased after 100 mM SC-aad9 treatment ( Figure  7a,b) .
SC-aad9 decreased Cdk4 kinase activity in synchronous tsFT210 cell
To determine if the phosphorylated Cdk4 was functionally inactivated or not, we measured Cdk4 kinase activity in vitro. We treated tsFT210 cells with 4100 mM SC-aad9 for 6 h, immunoprecipitated Cdk4 from the cell lysates and then determined its kinase activity using GST-Rb as a substrate. As shown in Figure 8 , treatment with SC-aad9 eectively blocked the Cdk4 kinase activity in a concentration dependent manner.
We also determined whether or not the compound aected the association between Cdk and cyclin. After SC-aad9 treatment for 6 h, we immunoprecipitated Cdk2 from cell lysates with an anti-Cdk2 antibody and then examined cyclin A and E content by Western blotting. We also immunoprecipitated Cdk4 from cell lysates with anti-Cdk4 and determined cyclin D1 protein levels. We ensured an equivalent loading of Cdk2 or Cdk4 with anti-Cdk2 or anti-Cdk4, respectively (Figure 9a,b) . Cyclin A or E association with Cdk2 did not change after SC-aad9 treatment ( Figure  9a ). Moreover, interaction between Cdk4 and cyclin D1 was also unaected by the treatment (Figure 9b ).
SC-aad9 did not alter p53, p21 or p16 levels
To ensure the inhibition of Cdk4 kinase activity and cell cycle arrest were not secondary to p53 induction or increased Cdk inhibitors, we measured p53, p21 and p16 levels in tsFT210 cells after SC-aad9 treatment ( Figure 10 ). tsFT210 cells treated with an equitoxic etoposide concentration displayed elevated p53 levels while SC-aad9 produced no increase (Figure 10a ). We also saw no increase in p21 or p16 with SC-aad9 (Figure 10b,c) . Both SC-aa09 and FY2-aa09 failed to arrest tsFT210 cells Previous studies indicated the benzyl moiety attached to the ethyl-diamine structure of SC-aad9 was essential for in vitro Cdc25 inhibitory activity (Figure 1 ). Recent studies indicate that a 18 : 82 mixture containing two substances (FY2-aa09), namely 4(4-[(2,5-diphenyl-oxazole-4-carbonyl)-amino]-cyclohexyl)-(carbonyl)-2-decanoylamino butyric acid, which has a more rigid chemical core than SC-aad9, and 2-decanoylamino-5-oxo-5-pyrrolidin-1-yl-pentanoic acid, which was a synthetic precursor, did not inhibit Cdc25 phosphatase in vitro . 4-(2-[(2, 5-diphenyl-oxazole-4-carbonyl)-amino]-ethyl)-carbamoyl)-2-decanoylamino butyric acid (SC-aa09) also had no inhibitory activity against Cdc25 phosphatase in vitro . To determine whether or not the cell cycle regulation by SC-aad9 was based on its Cdc25 inhibitory activity, we tested the ability of SC-aa09 and FY2-aa09, which are biochemically inactive and close structural congeners of SC-aad9, to eect cell cycle progression, Cdc2 phosphorylation status, and Cdk4 kinase activity. As shown in Figure 8 Eect of SC-aad9 on Cdk4 kinase activity in tsFT210 cells. Synchronized tsFT210 cells were cultured for 6 h at 32.08C and then incubated for an additional 6 h in the presence of 0 mM (lane 1), 50 mM (lane 2), 100 mM (lane 3) SC-aad9, FY2-aa09, or SC-aa09, respectively. The cells were harvested and sonicated in lysis buer. Cdk4 kinase activity was assayed using the Cdk4 immunocomplexes and GST-Rb as a substrate Figures 2 and 4 , neither 100 mM SC-aa09 nor FY2-aa09 blocked G1 or G2/M cell cycle progression. These compounds also did not aect Cdc phosphorylation or Cdk4 kinase activity (Figures 5 and 8) , supporting the hypothesis that Cdc25 inhibition could be causal for the cell cycle inhibition, and the altered biochemical endpoints.
Discussion
The Cdc25 family has an essential role in controlling cell proliferation. Cdc25A is responsible for G1 transition into S phase by regulating the activities of cyclin-dependent kinases (Homann et al., 1994) . Cdc25B probably initiates cellular movement through the G2 phase (Garner-Hamrick and Fisher, 1998; Lammer et al., 1998) while Cdc25 is required for entry into mitosis due to its ability to dephosphorylate and activate Cdc2 (Lammer et al., 1998; Strausfeld et al., 1994) . Cdc25A and B and have been reported to be eectors of the oncogene myc (Galaktionov et al., 1996) and a signi®cant number of human tumors overexpress Cdc25A or B (Galaktionov et al., 1995a; Gasparotto et al., 1997; Hernandez et al., 1998; Wu et al., 1998) . Cdc25A and B have also been reported to be oncogenic (Galaktionov et al., 1995a) . Thus, inhibitors to Cdc25 would be desirable. While each Cdc25 family member appears to have distinct biological functions, the amino acids in the active site HC(X 5 )R region are identical suggesting inhibitors with speci®city to all three CDc25s are feasible.
Except for the widely used broad-spectrum protein phosphatase inhibitor vanadate (Baratte et al., 1992) , few dual speci®city protein phosphatase inhibitors have been reported (Peng et al., 1998) . Although the natural products dnacin, dysidiolide, a RK-682 analogue and a cholestenone analog appear to inhibit Cdc25 dual speci®city phosphatase (Gunasekera et al., 1996; Hamaguchi et al., 1995; Horiguchi et al., 1994; Peng et al., 1998) , there is little information on the nature of their inhibition and selectivity, and these analogs are generally in limited supply. Moreover, the eects of these compounds on cell cycle transition are not known. That inhibition of Cdc25 activity can aect cell cycle transit through G2/M phase has been established using yeast and tsFT210 cells (Izumi and Maller, 1993; Millar et al., 1991; Th'ng et al., 1990) . The role of Cdc25 isoforms in controlling G1/S phase transit is supported by antisense studies (GarnerHamrick and Fisher, 1998) . Using parallel chemistry, we have previously synthesized on solid support a library of small molecules, non-electrophilic oxazoles that were designed as inhibitors of phosphatases . One compound in the library, SC-aad9, was among the most potent synthetic inhibitors of all Cdc25 dual speci®city phosphatases . Interestingly, the compound selectively inhibited growth of SV40 large T antigen transformed mouse embryonic ®broblasts (MEF), which overexpress Cdc25B, compared with non-transformed cells , suggesting some speci®c toxicity for the compound against malignant cells.
In this study, we showed for the ®rst time that SCaad9 inhibited cell cycle progression at both G1 and G2/M. We used the well controlled tsFT210 cell system because the cells can be synchronized without any agents or drugs. Both SC-aa09 and FY2-aa09, which are close congeners of SC-aad9, failed to block cell cycle progression. Neither FY2-aa09 nor SC-aa09 has inhibitory activity against Cdc25 phosphatases in vitro. These data revealed a close relation between Cdc25 inhibition in vitro and disruption of cell cycle regulation. Additional biochemical evidence for Cdc25 inhibition came from the eect on Cdc2 phosphorylation status. Based on the phosphorylation status of Cdc2, SC-aad9 appeared to act prior to nocodazole making it a potentially useful agent. SCaad9, but not the other closely related but biochemically inactive analogs, increased Cdc2 phosphorylation status in the intact cells. These concentration-response studies suggest SC-aad9 had an eect on Cdc25 within the cell and couples the blockage at G2/M with enzyme inhibition.
We hypothesized that inhibition of Cdc25A was responsible for the G1 block caused by SC-aad9, as Cdc25A seems to be important for entry into S phase (Hamaguchi et al., 1995; Homann et al., 1994; Jinno et al., 1994) . The tyrosine phosphorylation status of both Cdk2 and Cdk4 was markedly increased by SCaad9; both of these cyclin-dependent kinases have a central role in regulating the G1 transition (Hunter and Pines, 1994) . Cdc25A dephosphorylates the Cdc2/cyclin E complex at Thr14 and Tyr 15, which is required for progression through S phase (Homann et al., 1994; Sebastian et al., 1993) . Cdc25A controls the tyrosine phosphorylation status of Cdk4, which regulates G1 arrest induced by ultraviolet irradiation (Terada et al., 1995) and cell cycle re-entry from quiescence (Jinno et al., 1999) . Furthermore, Cdc25A determines the phosphorylation status of Rb through its eects on Cdk4 kinase. Our study demonstrated that SC-aad9 decreased Cdk4 kinase activity against GST-Rb protein, suggesting that dephosphorylation of Rb might cause the G1 block in tsFT210.
We can not formally exclude that SC-aad9 acts on other cell cycle control mechanisms. For example, Galaktinov et al. (1995b) reported the formation of complexes between Raf-1 kinase and Cdc25A in human and mouse somatic cells suggesting that Cdc25A is activated by Raf-1 kinase, which itself is a target of the oncogene Ras. Oncogenes, such as c-Myc, Ras, or Raf can enhance apoptotic responses to stimuli such as growth factor deprivation (Hunter and Pines, 1994) . We have recently reported that SC-aad9 decreased insulin-like growth factor-1 receptor tyrosine phosphorylation, and also inactivated mitogen-activated protein kinase (MAPK) in SV40 large T antigen transformed MEF . Because Raf-1 can control MAPK activity, inhibition of this pathway may also be important in the G1 arrest by SC-aad9.
It is well established that DNA damage, such as ionizing radiation, produce a p53 induction and block the cell cycle at both G1 and G2/M (Hermeking et al., 1997) . Our results indicate, however, exposure of tsFT210 cells to 100 mM SC-aad9 for 6 h did not produce either p53, p21, or p16 induction (Figure 10 ). These data suggest that the main pathway causing the dual cell cycle arrest by SCaad9 is dierent from p53 (p21) or p16 induction pathways.
In summary, we demonstrate that SC-aad9, which is an eective inhibitor of Cdc25, arrested cells in both G1 and Dual G1 and G2/M inhibition by SC-aad9 K Tamura et al G2/M phase. SC-aad9 increased the phosphorylation level of Cdc2 or Cdk2 and Cdk4, which are potent cell cycle regulators at G2/M and G1 checkpoints, respectively. We suggest small molecule inhibitors derived from the SC-aad9 pharmacophore will be useful for furthering our understanding of the role of Cdc25 in regulating G1 and G2 transition, and may contribute to a further development of novel anticancer agents.
Materials and methods

Materials
The general synthesis of compounds SC-aad9, SC-aa09, and FY2-aa09 has been previously described (Figure 1 ) Wipf et al., 1997) . The nomenclature for the fundamental SC pharmacophore or core chemical backbone has been described . The FY2 core structure represents a more rigid backbone, which is a component of a newer library that will be described elsewhere. The nomenclature for the modular components of SC-aa09 was described previously , where a is a phenyl moiety, d is a benzyl, 9 is a nonyl moiety and 0 re¯ects the lack of an alkyl or aromatic moiety. All compounds were suspended in DMSO as a stock solution. tsFT210 cells were a gift from Dr Chris Norbury (Oxford University, Oxford, UK) and were maintained for no longer than 30 passages (Th'ng et al., 1990) . The GST-Rb protein and anti-Cd2 (sc-54), anti-Cdk2 (sc-163G), anti-Cdk4 (sc-601G), anti-cyclin E (sc-481), anti-cyclin D1 (sc-6281), antip53 (sc-1312), anti-p21 (sc-397G) and anti-p16 (sc-1207) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibody agarose conjugate of each was used for immunoprecipitation. Anti-cyclin A antibody (CC17) was purchased from Oncogene Research Product (Cambridge, MA, USA). Anti-Phosphotyrosine mouse monoclonal IgG 2bk (05-321) was purchased from Upstate Biotechnology (Lane Placid, NY, USA). [g-32 P] ATP (10 mCi/ ml) was obtained from Amersham Life Science Inc. (Arlington Heights, IL, USA).
Flow cytometric analysis tsFT210 cells were plated at 2610 5 cells/ml and maintained at 32.08C as previously described (Th'ng et al., 1990) . Cell proliferation was blocked at G2 phase by incubation at 39.48C for 17 h. The synchronized cells were then released by re-incubating at 32.08C and treated immediately with SC-aad9, SC-aa09 or FY2-aa09, respectively, to probe for G2/M arrest (Figures 2 and 3) . Cells were treated 6 h after G2/M release to determine G1 arrest (Figure 4) . DMSO was used as a negative control and nocodazole (for G2/M) or roscovitine (for G1) as positive controls. Treated cells were incubated at 32.08C for an additional 6 h after each drug exposure, and then harvested with phosphate buered saline at 5610 5 cells/ml. The harvest cells were stained with a solution containing 50 mg/ml propidium and 250 mg/ml RNase A. Flow cytometry analysis was conducted with a Becton Dickinson FACS Star (Franklin Lakes, NJ, USA). Each compound was tested at least three independent times.
Western blotting analysis
Protein lysates of tsFT210 were harvested and analysed by Western blotting for Cdc2, p53, p21 and p16 as described previously . To quantify the phosphorylation level of Cdc2, we scanned X-ray ®lms on a Molecular Dynamics personal SI densitometer and analysed them using the Image Quant software package (Ver. 4.1, Molecular Dynamics, Sunnyvale, CA, USA). The phosphorylation ratio (P/U) was calculated by using the formula; P/U=(a)/(b), where (a) was the intensity of the phosphorylated band and (b) was the intensity of the unphosphorylated band, respectively.
Immunoprecipitation tsFT210 cells were harvested and sonicated in the lysis buer using the same procedure for cell synchronizing and drug exposure as described above for the G1¯ow cytometric analysis. Immunoprecipitation assays were performed essentially as described previously (Kakeya et al., 1998) , except we replaced 0.1% Tween 20 for 1% Triton X-100 in the lysis buer. We incubated 2 mg of protein lysate with 10 mg of anti-Cdk2 (rabbit polyclonal IgG) or anti-Cdk4 (goat polyclonal IgG) agarose conjgate for 4 h at 48C on a rocker platform. The immunocomplexes were washed four times with the same lysis buer. After the ®nal wash, the immunocomplexes were suspended with SDS-electrophoresis loading buer and analysed by Western blotting for Cdk2, tyrosine phosphorylated Cdk2, Cdk4, tyrosine phosphorylated Cdk4, cyclin A, cyclin E, and cyclin D1 as described above.
To quantify the phosphorylation level of Cdk2 or Cdk4, we scanned X-ray ®lms and analysed band intensity as described above. The phosphorylation level (pCdk2/Cdk2) was calculated by using the formula; pCdk2/Cdk2=(a)/(b), where (a) was the intensity of the phosphorylated Cdk2 band and (b) was the intensity of the Cdk2 band, respectively. Statistical signi®cance was analysed using Student's unpaired t-test.
Cdk4 kinase activity
Cdk4 immunocomplexes were prepared as described in the Immunoprecipitation Section above, and suspended with 20 ml of kinase reaction buer (Kakeya et al., 1998) . Rb protein was incubated with the immunocomplexes containing [g-32 P]ATP for 20 min at 308C. The proteins were separated by SDS ± PAGE and analysed with a Molecular Dynamics STORM 860 PhosphoImager (Sunnyvale, CA, USA).
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